- Conditions
- Heavy Menstrual Bleeding
- Interventions
- Tranexamic Acid
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 10 Years to 19 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • Kansas City, Missouri • Akron, Ohio + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Von Willebrand Disease, Type 1, Heavy Menstrual Bleeding
- Interventions
- Volta System
- Device
- Lead sponsor
- Five Liters, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Menorrhagia
- Interventions
- Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation
- Drug · Device
- Lead sponsor
- Abimbola Famuyide
- Other
- Eligibility
- 30 Years to 55 Years · Female only
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Menstruation; Heavy
- Interventions
- Nighttime Feminine Product
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
- Interventions
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Daniel Benjamin
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3,520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 43
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
- Conditions
- Adenomyosis
- Interventions
- Vaginal Bromocriptine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years to 55 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heavy Menstrual Bleeding, Menorrhagia, Hypermenorrhea
- Interventions
- Norethindrone acetate pretreatment, No pretreatment
- Drug · Other
- Lead sponsor
- Scott and White Hospital & Clinic
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Temple, Texas
- Conditions
- Menorrhagia
- Interventions
- Cerene(R) Cryotherapy Device
- Device
- Lead sponsor
- Channel Medsystems
- Industry
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 9
- States / cities
- Arlington Heights, Illinois • Naperville, Illinois • Fort Wayne, Indiana + 6 more
- Conditions
- Heavy Menstrual Bleeding
- Interventions
- Web-based data collection, Paper-based data collection
- Other
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 76
- States / cities
- Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more
- Conditions
- Uterine Fibroids
- Interventions
- Vilaprisan (BAY1002670), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Arcadia, California • Cerritos, California + 43 more
- Conditions
- Uterine Fibroids, Heavy Menstrual Bleeding
- Interventions
- OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back
- Drug
- Lead sponsor
- ObsEva SA
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 23
- States / cities
- Chino, California • Huntington Park, California • San Diego, California + 19 more
- Conditions
- Menorrhagia
- Interventions
- tranexamic acid
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 16 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Heavy Menstrual Bleeding
- Interventions
- Volta System
- Device
- Lead sponsor
- Spark Biomedical, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Menorrhagia, Heavy Menstrual Bleeding
- Interventions
- Tranexamic acid tablets (XP12B)
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 784 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 47 more
- Conditions
- Uterine Fibroids (UF)
- Interventions
- Not listed
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Arlington, Virginia
- Conditions
- Uterine Fibroids, Endometriosis
- Interventions
- Relugolix Combination Tablet
- Drug
- Lead sponsor
- Sumitomo Pharma Switzerland GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 120
- States / cities
- Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroids
- Interventions
- Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 155
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more
- Conditions
- Menorrhagia
- Interventions
- Intrauterine Ultrasound-Guided Radiofreq. Ablation System
- Device
- Lead sponsor
- Gynesonics
- Industry
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Denver, Colorado • Newark, Delaware + 19 more
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroid
- Interventions
- Relugolix, Estradiol/norethindrone acetate
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 104
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Mobile, Alabama + 84 more
- Conditions
- Iron Deficiency Anemia, Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
- Interventions
- Ferrous sulfate
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 9 Years to 22 Years · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Menorrhagia
- Interventions
- Tranexamic acid
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 92
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 79 more
- Conditions
- Menstrual Bleeding, Heavy
- Interventions
- Sample Collection and Endometrial Biopsy
- Procedure
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon